Literature DB >> 33495094

Chemokine networks modulating natural killer cell trafficking to solid tumors.

Xue Yao1, Sandro Matosevic2.   

Abstract

Natural killer (NK) cell-based cell therapy has been emerging as a powerful weapon in the treatment of multiple malignancies. However, the inadequate infiltration of the therapeutic NK cells into solid tumors remains a big challenge to their clinical utility. Chemokine networks, which play essential roles in the migration of lymphocytes, have been recognized as critical in driving the intratumoral infiltration of NK cells via interactions between soluble chemokines and their receptors. Often, such interactions are complex and disease-specific. In the context of NK cells, chemokine receptors of note have included CCR2, CCR5, CCR7, CXCR3, and CX3CR1. The immunobiology of chemokine-receptor interactions has fueled the development of approaches that hope to improve the infiltration of NK cells into the microenvironment of solid tumors. Stimulation of NK cells ex vivo in the presence of various cytokines (such as IL-2, IL-15, and IL-21) and genetic engineering of NK cells have been utilized to alter the chemokine receptor profile and generate NK cells with higher infiltrating capacity. Additionally, the immune-suppressive tumor microenvironment has also been targeted, by introducing, either directly or indirectly, chemokine ligands which NK cells are able to respond to, ultimately creating a more hospitable niche for NK cell trafficking. Such strategies have promoted the infiltration and activity of infused NK cells into multiple solid tumors. In this review, we discuss how chemokine receptors and their ligands coordinate and how they can be manipulated to regulate the trafficking, distribution, and residence of NK cells in solid tumors.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemokine receptors; Chemokines; Immunotherapy; Natural killer cells; Solid tumors

Year:  2021        PMID: 33495094     DOI: 10.1016/j.cytogfr.2020.12.003

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  8 in total

1.  Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular Carcinoma Via Inflammation of Tumor Immune Microenvironment and Suppression of Angiogenesis.

Authors:  Zhou Tian; Baojian Hong; Jianzhong Chen; Zhe Tang
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

Review 2.  Natural killer cell homing and trafficking in tissues and tumors: from biology to application.

Authors:  Guang He Ran; Yu Qing Lin; Lei Tian; Tao Zhang; Dong Mei Yan; Jian Hua Yu; You Cai Deng
Journal:  Signal Transduct Target Ther       Date:  2022-06-29

3.  CCR7 Has Potential to Be a Prognosis Marker for Cervical Squamous Cell Carcinoma and an Index for Tumor Microenvironment Change.

Authors:  Wei-Jie Tian; Peng-Hui Feng; Jun Wang; Ting Yan; Qing-Feng Qin; Dong-Lin Li; Wen-Tong Liang
Journal:  Front Mol Biosci       Date:  2021-04-01

Review 4.  Natural Killer Cells in the Malignant Niche of Multiple Myeloma.

Authors:  Ondrej Venglar; Julio Rodriguez Bago; Benjamin Motais; Roman Hajek; Tomas Jelinek
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

Review 5.  Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy.

Authors:  Mubin Tarannum; Rizwan Romee; Roman M Shapiro
Journal:  Front Immunol       Date:  2022-03-25       Impact factor: 7.561

Review 6.  Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.

Authors:  Philippa R Kennedy; Martin Felices; Jeffrey S Miller
Journal:  Stem Cell Res Ther       Date:  2022-04-12       Impact factor: 6.832

7.  Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours.

Authors:  Yuji Sano; Yumiko Azuma; Toshiaki Tsunenari; Yoko Kayukawa; Junko Shinozuka; Etsuko Fujii; Jun Amano; Yukari Nishito; Toru Maruyama; Yasuko Kinoshita; Yuichiro Sakamoto; Ayae Yoshida; Yoko Miyazaki; Yuta Sato; Chifumi Teramoto-Seida; Takahiro Ishiguro; Takayoshi Tanaka; Takehisa Kitazawa; Mika Endo
Journal:  Nat Commun       Date:  2022-09-07       Impact factor: 17.694

Review 8.  Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.

Authors:  Cristina Capuano; Chiara Pighi; Simone Battella; Davide De Federicis; Ricciarda Galandrini; Gabriella Palmieri
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.